Rigel Pharmaceuticals, Inc. (RIGL)
$46.82-0.68%Close
BUYBEAR · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $866M
- Beta
- 1.19
- P/E (TTM)
- 2.65
- Short % float
- 15.98%
- Days to cover
- 11.1
- SI change
- -10.5%
- 1W
- -2.44%
- 1M
- +5.55%
- vs SPY 1W
- -2.30%
- vs SPY 1M
- +3.04%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 58
- VALUE
- 43
- GROWTH
- 71
- GARP
- 65
- TYPE
- Value / Recovery (blended)
Composite of Value · Growth · GARP
ROIC57.9%
REV YoY-
ROE96.5%
EPS YoY-
ROA61.8%
GROSS91
OP31
NET116
[VALUATION]
P/E TTM2.65
P/E FWD11.57
SECTOR PE20.48
INDUSTRY PE13.99
P/B2.04
P/FCF-
EV/EBITDA8.99
EV/EBIT-
PEG1.17
FCF YIELD-
RISK
INT COV-
D/E9.39
ALTMAN Z-
CURR RATIO1.95
ND/EBITDA-
BETA1.19
Company news
FAQ
- What is LOPJLB’s current signal on RIGL?
- LOPJLB’s latest quantitative signal on Rigel Pharmaceuticals, Inc. (RIGL) is BUY in a BEAR regime. Signals are updated daily.
- What market regime is RIGL in?
- Rigel Pharmaceuticals, Inc. (RIGL) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Rigel Pharmaceuticals, Inc. (RIGL) do?
- Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with rel…